drugset / Trial / NCT07356453
A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.
NaSequentialOpen-labelTreatment
Summary
The goal of this interventional study is to evaluate the safety and tolerability of escalating doses of FORX-48 as monotherapy in patients with select advanced solid tumors with BRCA1/2 mutations or other DDR deficiencies or high replication stress, and to determine the maximum tolerated dose (MTD) and Recommended Cohort Expansion Dose (RCED) of FORX-428 as monotherapy.
Timeline
- Start
- 2025-07-22
- Primary completion
- 2027-06
- Completion
- 2028-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FORX-428 | Unknown | 30 mg | Oral |
| Subject | FORX-428 | Unknown | 60 mg | Oral |
| Subject | FORX-428 | Unknown | 120 mg | Oral |
| Subject | FORX-428 | Unknown | 200 mg | Oral |
| Subject | FORX-428 | Unknown | 300 mg | Oral |
| Subject | FORX-428 | Unknown | 400 mg | Oral |